BioSpace News Archive

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, announced that the companies have entered into a technology partnership to expand Evotec’s antibody discovery platform.

Vicore Pharma Holding AB, a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders, reports an expanded data analysis to follow up the encouraging top line data from the ATTRACT study reported on December 8, 2020.

Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms

ViewRay, Inc. announced that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance.

AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Administration on December 17, 2020 granted Orphan Drug Designation status to AIM’s drug Ampligen (

Latex gloves are natural material, made out of rubber. Gloves are disposable items used during medical examinations and procedures intended to prevent cross-contamination between healthcare providers and patients.

Generally, the global market for intravascular temperature management has seen a significant growth and it is ready to encounter a period of positive development in the years to come.

Faricimab given every eight weeks and at personalized dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS® technology.